Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,

Slides:



Advertisements
Similar presentations
Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
Advertisements

Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
Impact of Anticoagulant and Anti-platelet Therapy on ICD Implant-Related Bleeding and Thromboembolic Events in Patients Enrolled in the NCDR ® ICD Registry.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Gillian D Sanders Ph.D.Lurdes Y Inoue Ph.D. Associate Professor of MedicineAssociate Professor of Biostatistics Duke UniversityUniversity of Washington.
CRT-D Effectiveness by QRS Duration and Morphology in the MADIT-CRT Patients Wojciech Zareba, MD, PhD, Helmut Klein, MD, Iwona Cygankiewicz, MD, PhD, W.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Preliminary results from the C-Pulse OPTIONS HF European Multicenter Post-Market Study Holger Hotz, CardioCentrum Berlin, Berlin, Germany; Antonia Schulz,
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Alon Barsheshet, MD1, Paul J. Wang, MD2, Arthur J. Moss, MD1, Scott D
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Ultra long term outcomes in adult survivors of tetralogy of Fallot and the effect of pulmonary valve replacement Dobson R1,2, Danton M2, Walker N2, Tzemos,
AICD usage for primary prevention at Mercy Hospital: successes, challenges and next steps Mohammad Tahir PGY-3.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
LONG-TERM SURVIVAL WITH CARDIAC RESYNCHRONIZATION THERAPY IN MILD HEART FAILURE PATIENTS Ilan Goldenberg, MD, Valentina Kutyifa, MD, PhD, Helmut Klein,
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Author Disclosures Differences in Implantation-Related Adverse Events Between Men and Women Receiving ICD Therapy for Primary Prevention Differences in.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Coverage with Evidence Development Implantable Cardioverter Defibrillators 1 Sean Tunis MD, MSc June 23, 2009.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Acute Lead Dislodgements in NCDR ® ICD Registry™ Patients Alan Cheng, MD, Yongfei Wang, MS, Jeptha P. Curtis, MD, Paul D. Varosy, MD Johns Hopkins University.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Prior studies have demonstrated racial/ethnic differences in access to innovative cardiovascular technologies. Background and Objectives Conclusions Data.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
Prospective Evaluation of EECP in Congestive Heart Failure (PEECH) Trial PEECH Trial Presented at The American College of Cardiology Scientific Sessions.
ICD Reimbursement Mortality by Intention-to-Treat Mortality Months of follow-up 36.1% 7.2% year.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Eric J Robinson, M.D. Cardiologist April 25, 2015
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
METHODS The EASYTRAK 2 lead was studied along with the CONTAK  RENEWAL  2/4/4HE device in the Device Evaluation of the CONTAK RENEWAL 2/4/4HE with EASYTRAK.
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
Total Occlusion Study of Canada (TOSCA-2) Trial
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
EMPHASIS-HF Extended Follow-up
ATHENA Trial Presented at Heart Rhythm 2008 in San Francisco, USA
Select Topics in Cardiovascular Medicine
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
Remote Patient Management:
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Volume 16, Issue 6, Pages (June 2019)
Presentation transcript:

Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman, M. Haim, JE. Schliamser, M. Boulos, S. Viskin, M. Swissa, N. Gavrielov-Yusim, T. Fuchs, M. Ilan, I. Goldenberg6, and M. Glikson6 April 23, 2013

BackgroundBackground Elderly patients (eg, age ≥75 or 80 years) and patients with major co-morbidities were excluded from some of the major ICD/CRTD trials, and few patients over age 75 were enrolled in any of the trials It is not known, therefore, what survival benefit elderly patients derive from device- based therapy Elderly patients (eg, age ≥75 or 80 years) and patients with major co-morbidities were excluded from some of the major ICD/CRTD trials, and few patients over age 75 were enrolled in any of the trials It is not known, therefore, what survival benefit elderly patients derive from device- based therapy

PurposePurpose To evaluate, the outcomes of elderly patients who received device-based therapy (ICD or CRT-D) in a “real- world” scenario

MethodsMethods Israeli ICD Registry Database Israeli ICD Registry Database Period: Jul 2010-June 2012 Period: Jul 2010-June 2012 Study end points Death Appropriate ICD therapies for VA Readmission to hospital for HF The combined endpoints of HF or death, VA or death Need for device related surgical re- intervention. Israeli ICD Registry Database Israeli ICD Registry Database Period: Jul 2010-June 2012 Period: Jul 2010-June 2012 Study end points Death Appropriate ICD therapies for VA Readmission to hospital for HF The combined endpoints of HF or death, VA or death Need for device related surgical re- intervention.

Baseline Characteristics Variable Age Group ≤65(n=137 8) (n=863) >75(n=566 ) p Percent of total population Female gender (%) Ethnicity Jews788893<0.001 Arabs22117<0.001 Medical History Heart Failure (%) NYHA I-II NYHA III NYHA IV122

Baseline Characteristics (cont’) Variable (%) Age Group ≤65(n=137 8) (n=863) >75(n=566 ) p Previous MI <0.001 CABG223843<0.001 PCI (61%)0.003 Dilated non-ischemic CM 30%1715<0.001 Atrial fibrillation162629<0.001 Cerebrovascular disease 611 <0.001 Diabetes334337<0.001 Hypertension557172<0.001 Dyslipidemia5060 <0.001 Chronic lung disease

Baseline Characteristics (cont’) Variable (%) Age Group ≤65(n=137 8) (n=863) >75(n=56 6) p Beta Blockers1130 (83%)699 (81%)445 (79%)0.2 ACE- I/ARB1009 (74%)648 (81%)420 (75%)0.48 Diuretics914 (67%)646 (75%)432 (77%)<0.001 Anti-arrhythmic drugs180 (14%)167 (20%)142 (26%)<0.001 Amiodaron128 (10%)116 (14%)101 (18%) Diagnostic studies LVEF<30%733 (54%)470 (55%)319 (57%) QRS duration, mean (ms)114±30122±30125±31<0.001 QRS>120 ms438 (32)365 (43%)254 (45%)<0.001 Electrophysiologic study205 (15%)155 (18%)104 (19%)0.06

Device implanted P<0.001 IndicationIndication

OutcomesOutcomes 1218 (84% male; age≤65, n=612; 66-75, n=376; >75, n=230) unselected registry patients were prospectively followed for the occurrence of clinical outcomes.

Death o HF in the General Population

Death or HF According to Device Type In ICD recipients In RCTD recipients

Death or VA in the General Population

Device-Related Complications Aassociated with Surgical Re-interventions

Multivariate analysis: Risk of HF/Death by age category (reference group =age<65) EndpointTotal PopulationICD RecipientsCRTD Recipients HRp P p HF or death Age < Age> < < HF Age Age>

Multivariate analysis: Risk of VA/Death by age category (reference group =age<65) EndpointTotal PopulationICD RecipientsCRTD Recipients HRp P p VT/VF or death Age Age> < < VT/VF Age Age>

Main Findings Of new ICDs and CRTDs implanted in Israel, >50% are in patients >65 yo and >20% in patients >75 yo Elderly patients have higher risk profile more likely to receive CRTD device > secondary prevention indication Of new ICDs and CRTDs implanted in Israel, >50% are in patients >65 yo and >20% in patients >75 yo Elderly patients have higher risk profile more likely to receive CRTD device > secondary prevention indication

Main Findings Our data add to and support the existing evidence from previous studies that the association between advanced age and adverse clinical outcomes is attenuated in elderly patients implanted with CRT-D devices.

Main Findings Elderly patients implanted with ICDs experienced a significant increase in the cumulative probability of the combined end- points of appropriate ICD therapy or death and HF or death In contrast, the risk of both HF and arrhythmic outcomes was attenuated among elderly patients implanted with CRT-D devices. Elderly patients implanted with ICDs experienced a significant increase in the cumulative probability of the combined end- points of appropriate ICD therapy or death and HF or death In contrast, the risk of both HF and arrhythmic outcomes was attenuated among elderly patients implanted with CRT-D devices.